Form 4: Halozyme Therapeutics CFO Nicole LaBrosse Reports Stock Option and Restricted Stock Unit Grants

Nicole LaBrosse, CFO of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• On February 23, 2024, Nicole LaBrosse, the SVP and CFO of Halozyme Therapeutics, Inc., was granted options to purchase 27,722 shares of common stock at an exercise price of $40.56.
• These options vest one-fourth on February 23, 2025, and then 1/48th monthly thereafter.
• LaBrosse also received 26,751 restricted stock units (RSUs) which vest one-fourth on each anniversary of the grant date, starting February 23, 2025.
• Following these transactions, LaBrosse directly owns 27,722 options and 26,751 RSUs.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is slightly positive due to the incentive structure.

Positives

• The grant of stock options and RSUs aligns the CFO's interests with those of the shareholders, incentivizing her to improve the company's performance.
• The vesting schedules encourage long-term commitment from the CFO.

Industry Context

Stock option and RSU grants are common practice for incentivizing executives in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates